Airway inflammation

“Airway inflammation” refers broadly to an immunopathological process involving infiltration and activation of various immune cells—including eosinophils, neutrophils, mast cells, basophils—and release of pro-inflammatory cytokines within the airways. This process underlies diseases such as asthma and COPD. It is characterized by increased vascular permeability; migration and activation of granulocytes; production of reactive oxygen species; disruption of epithelial barrier function; and chronic cycles leading to tissue remodeling[3][1][5]. Key molecular drivers include type 2 cytokines (such as IL‑4, IL‑5, IL‑13), chemokines (CCL22), adhesion molecules (ICAM‑1/VCAM‑1), pattern recognition receptors on epithelial cells detecting pathogens/allergens/damage signals[1][3]. While many drugs modulate this process by targeting specific mediators or pathways involved in airway inflammation—such as monoclonal antibodies against interleukins—the term “airway inflammation” does not refer to a single molecule or receptor but rather a complex pathological state[6][3]. Therefore it is not considered a canonical therapeutic target. In summary: “Airway inflammation” describes a pathobiological condition/process—not an individual molecule/receptor—and thus cannot be mapped directly onto structured fields for canonical drug targets.

Other names

Airway inflammationInflammatory airway diseaseAirway inflammatory response